Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60.

Article  PubMed  Google Scholar 

Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21–129.

Article  PubMed  Google Scholar 

Carciotto G, Costa F, Garcia-Ruiz V, Galli M, Soraci E, Magliarditi A, et al. Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review. J Clin Med. 2023;12(22):7144.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan SU, Kleiman NS. Optimizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Older Adults. JAMA Network Open. 2024;7(3):e246951-e.

Article  PubMed  Google Scholar 

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

Article  CAS  PubMed  Google Scholar 

Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Serruys PW, et al. Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. EuroIntervention. 2020;16(8):627–33.

Article  PubMed  Google Scholar 

Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019;321(24):2428–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim CJ, Park MW, Kim MC, Choo EH, Hwang BH, Lee KY, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305–16.

Article  CAS  PubMed  Google Scholar 

Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. JAMA Cardiol. 2022;7(4):407–17.

Article  PubMed  PubMed Central  Google Scholar 

Han JK, Hwang D, Yang S, Park SH, Kang J, Yang HM, et al. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial. Circulation. 2023;147(18):1358–68.

Article  CAS  PubMed  Google Scholar 

Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation. 2024;149(8):585–600.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.

Google Scholar 

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5:1–10.

Article  Google Scholar 

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47.

Article  PubMed  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.

Article  PubMed  Google Scholar 

Cochran WG. Some methods for strengthening the common χ 2 tests. Biometrics. 1954;10(4):417–51.

Article  Google Scholar 

Sterne JA, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Team RD. R: A language and environment for statistical computing. (No Title). 2010.

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. BMJ Ment Health. 2019;22(4):153–60.

Google Scholar 

McGuinness LA. robvis: An R package and web application for visualising risk-of-bias assessments. 2019. Github URL: https://github.com/mcguinlu/robvis. Accessed 2021–07–31.

Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340–8.

Article  CAS  PubMed  Google Scholar 

Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510–22.

CAS  PubMed  Google Scholar 

Kim B-K, Hong S-J, Cho Y-H, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kedhi E, Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, et al. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. Atherosclerosis. 2021;321:39–44.

Article  CAS  PubMed  Google Scholar 

Choi KH, Park YH, Song YB, Park TK, Lee JM, Yang JH, et al. Long-term effects of P2Y12 inhibitor monotherapy after percutaneous coronary intervention: 3-year follow-up of the SMART-CHOICE randomized clinical trial. JAMA Cardiology. 2022;7(11):1100–8.

Article  PubMed  PubMed Central  Google Scholar 

Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. The Lancet. 2018;392(10151):940–9.

Article  CAS  Google Scholar 

Landi A, Heg D, Frigoli E, Vranckx P, Windecker S, Siegrist P, et al. Abbreviated or standard antiplatelet therapy in HBR patients: final 15-month results of the MASTER-DAPT trial. Cardiovascular Interventions. 2023;16(7):798–812.

Article  PubMed  Google Scholar 

Hong S-J, Lee S-J, Suh Y, Yun KH, Kang TS, Shin S, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation. 2024;149(8):562–73.

Article  PubMed  Google Scholar 

Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Nishikawa R, et al. Clopidogrel vs aspirin monotherapy beyond 1 year after percutaneous coronary intervention. J Am Coll Cardiol. 2024;83(1):17–31.

Article  CAS  PubMed  Google Scholar 

Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–42.

Article  CAS  PubMed  Google Scholar 

Franzone A, et al. “Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting,” (in eng). J Am Coll Cardiol. 2019;74(18):2223–34. https://doi.org/10.1016/j.jacc.2019.08.1038.

Article  CAS  PubMed  Google Scholar 

Serruys PW, et al. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J. 2019;40(31):2595–604.